Douglas Huseby is a researcher and program manager for ENABLE-2 at the University of Uppsala in Uppsala, Sweden. His research career has focused on various topics in bacterial genetics, including evolution and mechanisms of antibiotic resistance and novel antibiotic development. He has worked since 2014 in the EU’s Innovative Medicines Initiative New Drugs 4 Bad Bugs ENABLE program, and the Swedish follow-on, ENABLE-2. These programs have worked to connect early-stage antibiotic development programs with experimental resources in academia, and expertise from pharmaceutical companies and academia to develop their projects. In these programs, he has worked on many antibiotic discovery and development projects, helping to identify the mechanism of action and resistance mechanisms to novel antimicrobial compounds.